D'Incalci M - Search Results

1

Trabectedin for the treatment of breast cancer.

D'Incalci M, Zambelli A. D'Incalci M, et al. Expert Opin Investig Drugs. 2016;25(1):105-15. doi: 10.1517/13543784.2016.1124086. Epub 2015 Dec 22. Expert Opin Investig Drugs. 2016. PMID: 26592307 Review.

2

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

Erba E, Bergamaschi D, Bassano L, Damia G, Ronzoni S, Faircloth GT, D'Incalci M. Erba E, et al. Eur J Cancer. 2001 Jan;37(1):97-105. doi: 10.1016/s0959-8049(00)00357-9. Eur J Cancer. 2001. PMID: 11165136

3

Development of distamycin-related DNA binding anticancer drugs.

Marchini S, Broggini M, Sessa C, D'Incalci M. Marchini S, et al. Expert Opin Investig Drugs. 2001 Sep;10(9):1703-14. doi: 10.1517/13543784.10.9.1703. Expert Opin Investig Drugs. 2001. PMID: 11772279 Review.

4

Unique features of the mode of action of ET-743.

D'Incalci M, Erba E, Damia G, Galliera E, Carrassa L, Marchini S, Mantovani R, Tognon G, Fruscio R, Jimeno J, Faircloth GT. D'Incalci M, et al. Oncologist. 2002;7(3):210-6. doi: 10.1634/theoncologist.7-3-210. Oncologist. 2002. PMID: 12065793 Free article. Review.

5

The combination of yondelis and cisplatin is synergistic against human tumor xenografts.

D'Incalci M, Colombo T, Ubezio P, Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R, Sessa C, Cavallini E, Jimeno J, Faircloth GT. D'Incalci M, et al. Eur J Cancer. 2003 Sep;39(13):1920-6. doi: 10.1016/s0959-8049(03)00490-8. Eur J Cancer. 2003. PMID: 12932672

6

Preclinical and clinical results with the natural marine product ET-743.

D'Incalci M, Jimeno J. D'Incalci M, et al. Expert Opin Investig Drugs. 2003 Nov;12(11):1843-53. Expert Opin Investig Drugs. 2003. PMID: 14585059 Review.

7

Fetal bovine serum, but not human serum, inhibits the in vitro cytotoxicity of ET-743 (Yondelis, trabectedin), an example of potential problems for extrapolation of active drug concentrations from in vitro studies.

Tognon G, Frapolli R, Zaffaroni M, Erba E, Zucchetti M, Faircloth GT, D'Incalci M. Tognon G, et al. Cancer Chemother Pharmacol. 2004 Jan;53(1):89-90. doi: 10.1007/s00280-003-0704-y. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586558 No abstract available.

8

Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.

Marchini S, Marrazzo E, Bonomi R, Chiorino G, Zaffaroni M, Weissbach L, Hornicek FJ, Broggini M, Faircloth GT, D'Incalci M. Marchini S, et al. Eur J Cancer. 2005 Jan;41(2):323-33. doi: 10.1016/j.ejca.2004.10.021. Eur J Cancer. 2005. PMID: 15661559

9

The unique biological features of the marine product Yondelis (ET-743, trabectedin) are shared by its analog ET-637, which lacks the C ring.

Erba E, Cavallaro E, Damia G, Mantovani R, Di Silvio A, Di Francesco AM, Riccardi R, Cuevas C, Faircloth GT, D'Incalci M. Erba E, et al. Oncol Res. 2004;14(11-12):579-87. doi: 10.3727/0965040042707925. Oncol Res. 2004. PMID: 15666999

10

New drugs from the sea.

D'Incalci M, Simone M, Tavecchio M, Damia G, Garbi A, Erba E. D'Incalci M, et al. J Chemother. 2004 Nov;16 Suppl 4:86-9. doi: 10.1179/joc.2004.16.Supplement-1.86. J Chemother. 2004. PMID: 15688619 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

560 results

Search Page